| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Aug, 2026 | Aug, 2026 | Aug, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -8,990 | -30,360 | 0 | 0 | 0 |
| Net Income Growth | +70.39% | unch | unch | unch | unch |
Polaryx Therapeutics Inc (PLYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Polaryx Therapeutics Inc. is a clinical-stage biotechnology company focused on development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders. Polaryx Therapeutics Inc. is based in PARAMUS, NJ.
Fiscal Year End Date: 12/31